Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

968
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
968
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

417
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
417
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

1.7K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.7K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

821
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
821
Pharmacovigilance01:19

Pharmacovigilance

961
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
961
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

141
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
141

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of lipoprotein(a) and peripheral artery disease: Findings from The hispanic community health study/study of latinos (HCHS/SOL).

American journal of preventive cardiology·2026
Same author

Delta-9-tetrahydrocannabutol (Δ9-THCB), Delta-9-tetrahydrocannabihexol (Δ9-THCH), and Delta-9-tetrahydrocannabiphorol (Δ9-THCP): the Impact of Varying Alkyl Chain Length on Delta-9-tetrahydrocannabinol (Δ9-THC) Analog Metabolism.

Journal of analytical toxicology·2026
Same author

The Association Between Traumatic Brain Injury and Cardiovascular Disease: A Systematic Review and Meta-Analysis.

The Journal of head trauma rehabilitation·2026
Same author

Clinician-level variation in lipid management for secondary prevention of atherosclerotic cardiovascular disease: Opportunities for practice improvement.

American journal of preventive cardiology·2026
Same author

Cardiovascular Testing and Changes in Lipid-Lowering Therapy After Coronary Artery Calcium Scoring.

JACC. Advances·2026
Same author

Aromatase inhibitors induce pain-like musculoskeletal symptoms in mice: behavioural, pharmacological and pathophysiological characterization.

British journal of pharmacology·2026

Related Experiment Video

Updated: Aug 24, 2025

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

7.5K

Ivabradine toxicity: a case report.

Kavisha Singh1, Muthukumar R Alagarraju1, Carl E Wolf2

  • 1Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX, 75390-8830, USA.

Journal of Medical Case Reports
|October 24, 2022
PubMed
Summary
This summary is machine-generated.

This case study highlights ivabradine toxicity causing symptomatic bradycardia. Measuring serum ivabradine levels confirmed the diagnosis, offering insights into drug toxicity management.

Keywords:
ArrhythmiasCardiologyCase reportPharmacokinetics

More Related Videos

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

9.9K
Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology
10:41

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Published on: September 13, 2022

2.2K

Related Experiment Videos

Last Updated: Aug 24, 2025

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

7.5K
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

9.9K
Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology
10:41

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Published on: September 13, 2022

2.2K

Area of Science:

  • Cardiology
  • Clinical Pharmacology

Background:

  • Ivabradine is a medication used to treat heart conditions.
  • Symptomatic bradycardia is a significant adverse effect that can occur with certain medications.

Observation:

  • A 43-year-old female experienced syncope and dizziness due to a heart rate of 50 bpm.
  • She was taking ivabradine for inappropriate sinus tachycardia.

Findings:

  • Diagnosis of ivabradine toxicity was made through serum ivabradine level measurement.
  • This diagnostic approach is not yet widely clinically available.

Implications:

  • Serum ivabradine level measurement can confirm toxicity.
  • Understanding ivabradine pharmacokinetics is crucial for diagnosing and managing toxicity.